Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.

Stroke - 1 Apr 2026

Lin Jinxi, Zhou Hongyu, Wang Yubo, Jin Aoming, Li Shangzhi, Zhang Ling, Meng Xia, Xie Xuewei, Jing Jing, Jiang Yong, Wang Yilong, Zhao Xingquan, Li Hao, Li Zixiao, Wang Yongjun

Abstract excerpt

BACKGROUND: Lp-PLA2 (lipoprotein-associated phospholipase A2) is a sensitive biomarker of vascular inflammation and atherosclerosis. This study evaluated the influence of Lp-PLA2 activity on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin among patients with minor stroke or transient ischemic attack carrying CYP2C19 loss-of-function alleles. METHODS: The CHANCE-2 trial (Clopidogrel in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 1-Alkyl-2-acetylglycerophosphocholine Esterase
Share to Aspirin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C19

Share to Ischemic Attack, Transient

Share to Platelet Aggregation Inhibitors

Share to Stroke

Share to Ticagrelor

Source

Open in PubMed Open full text

Identifiers

PMID: 41527826
DOI: 10.1161/STROKEAHA.125.052954
PMCID: PMC13003939

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.PMID 41527826Read ↗

Efficacy of dual antiplatelet therapy after ischemic stroke according to hsCRP levels and CYP2C19 genotype.Semantic proximity Read ↗

Genotype-guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE-2.Semantic proximity Read ↗

Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with CYP2C19 loss of function alleles: a systematic review and meta-analysis.Semantic proximity Read ↗

Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.Semantic proximity Read ↗

Efficacy of Dual Antiplatelet therapy depending on hsCRP levels and CYP2C19 GenotypeSemantic proximity Read ↗

Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack.Semantic proximity Read ↗

Dual antiplatelet therapy with ticagrelor vs clopidogrel in patients with TIA or minor stroke with or without symptomatic carotid artery stenosis: a post hoc analysis of the CHANCE-2 trial.Semantic proximity Read ↗

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.Semantic proximity Read ↗

Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack With a Single Small Subcortical Infarction.Semantic proximity Read ↗

The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis.Semantic proximity Read ↗

Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies.Semantic proximity Read ↗

Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.